Journal Article > ResearchAbstract Only
AIDS. 24 November 2022; Volume 37 (Issue 3); 513-522.; DOI:10.1097/QAD.0000000000003442
Patten GE, Euvrard J, Anderegg N, Boulle AM, Arendse KD, et al.
AIDS. 24 November 2022; Volume 37 (Issue 3); 513-522.; DOI:10.1097/QAD.0000000000003442
OBJECTIVE
Despite improved access to antiretroviral therapy (ART) for people with HIV (PWH), HIV continues to contribute considerably to morbidity and mortality. Increasingly, advanced HIV disease (AHD) is found among PWH who are ART-experienced.
DESIGN
Using a multi-state model we examined associations between engagement with care and AHD on ART in South Africa.
METHODS
Using data from IeDEA Southern Africa, we included PWH from South Africa, initiating ART from 2004 to 2017 aged more than 5 years with a CD4+ cell count at ART start and at least one subsequent measure. We defined a gap as no visit for at least 18 months. Five states were defined: ‘AHD on ART’ (CD4+ cell count <200 cells/μl), ‘Clinically Stable on ART’ (CD4+ cell count ≥200 or if no CD4+ cell count, viral load <1000 copies/ml), ‘Early Gap’ (commencing ≤18 months from ART start), ‘Late Gap’ (commencing >18 months from ART start) and ‘Death’.
RESULTS
Among 32 452 PWH, men and those aged 15–25 years were more likely to progress to unfavourable states. Later years of ART start were associated with a lower probability of transitioning from AHD to clinically stable, increasing the risk of death following AHD. In stratified analyses, those starting ART with AHD in later years were more likely to re-engage in care with AHD following a gap and to die following AHD on ART.
CONCLUSION
In more recent years, those with AHD on ART were more likely to die, and AHD at re-engagement in care increased. To further reduce HIV-related mortality, efforts to address the challenges facing these more vulnerable patients are needed.
Despite improved access to antiretroviral therapy (ART) for people with HIV (PWH), HIV continues to contribute considerably to morbidity and mortality. Increasingly, advanced HIV disease (AHD) is found among PWH who are ART-experienced.
DESIGN
Using a multi-state model we examined associations between engagement with care and AHD on ART in South Africa.
METHODS
Using data from IeDEA Southern Africa, we included PWH from South Africa, initiating ART from 2004 to 2017 aged more than 5 years with a CD4+ cell count at ART start and at least one subsequent measure. We defined a gap as no visit for at least 18 months. Five states were defined: ‘AHD on ART’ (CD4+ cell count <200 cells/μl), ‘Clinically Stable on ART’ (CD4+ cell count ≥200 or if no CD4+ cell count, viral load <1000 copies/ml), ‘Early Gap’ (commencing ≤18 months from ART start), ‘Late Gap’ (commencing >18 months from ART start) and ‘Death’.
RESULTS
Among 32 452 PWH, men and those aged 15–25 years were more likely to progress to unfavourable states. Later years of ART start were associated with a lower probability of transitioning from AHD to clinically stable, increasing the risk of death following AHD. In stratified analyses, those starting ART with AHD in later years were more likely to re-engage in care with AHD following a gap and to die following AHD on ART.
CONCLUSION
In more recent years, those with AHD on ART were more likely to die, and AHD at re-engagement in care increased. To further reduce HIV-related mortality, efforts to address the challenges facing these more vulnerable patients are needed.
Journal Article > CommentaryAbstract Only
Clin Infect Dis. 29 August 2022; Volume 76 (Issue 3); e773-e775.; DOI:10.1093/cid/ciac689
Burry J, Casas CP, Ford NP
Clin Infect Dis. 29 August 2022; Volume 76 (Issue 3); e773-e775.; DOI:10.1093/cid/ciac689
Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. World Health Organization guidelines strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.
Journal Article > ResearchFull Text
Lancet. 8 December 2001; Volume 358 (Issue 9297); DOI:10.1016/S0140-6736(01)06995-1
Shafer J, Falzon D, Small I, Kittle D, Ford NP
Lancet. 8 December 2001; Volume 358 (Issue 9297); DOI:10.1016/S0140-6736(01)06995-1
Journal Article > ResearchFull Text
Trop Med Int Health. 1 December 2010; Volume 15 (Issue 12); DOI:10.1111/j.1365-3156.2010.02649.x
Bemelmans M, van den Akker T, Ford NP, Philips M, Zachariah R, et al.
Trop Med Int Health. 1 December 2010; Volume 15 (Issue 12); DOI:10.1111/j.1365-3156.2010.02649.x
Objective To describe how district-wide access to HIV/AIDS care was achieved and maintained in Thyolo District, Malawi. Method In mid-2003, the Ministry of Health and Médecins Sans Frontières developed a model of care for Thyolo district (population 587 455) based on decentralization of care to health centres and community sites and task shifting. Results After delegating HIV testing and counseling to lay counsellors, uptake of testing increased from 1300 tests per month in 2003 to 6500 in 2009. Shifting responsibility for antiretroviral therapy (ART) initiations to non-physician clinicians almost doubled ART enrolment, with a majority of initiations performed in peripheral health centres. By the end 2009, 23 261 people had initiated ART of whom 11 042 received ART care at health-centre level. By the end of 2007, the universal access targets were achieved, with nearly 9000 patients alive and on ART. The average annual cost for achieving these targets was €2.6 per inhabitant/year. Conclusion The Thyolo programme has demonstrated the feasibility of district-wide access to ART in a setting with limited resources for health. Expansion and decentralization of HIV/AIDS service-capacity to the primary care level, combined with task shifting, resulted in increased access to HIV services with good programme outcomes despite staff shortages.
Journal Article > LetterFull Text
Lancet. 13 April 2002; Volume 359 (Issue 9314); 1351.; DOI:10.1016/S0140-6736(02)08303-4
Ford NP, 't Hoen E
Lancet. 13 April 2002; Volume 359 (Issue 9314); 1351.; DOI:10.1016/S0140-6736(02)08303-4
Journal Article > CommentaryFull Text
Lancet. 10 June 2000; Volume 355 (Issue 9220); 2067-2068.; DOI:10.1016/S0140-6736(00)02364-3
de Jong J, Mulhern M, Ford NP, van der Kam S, Kleber RJ
Lancet. 10 June 2000; Volume 355 (Issue 9220); 2067-2068.; DOI:10.1016/S0140-6736(00)02364-3
Journal Article > ResearchFull Text
Disasters. 1 June 2003; Volume 27 (Issue 2); 141-153.; DOI:10.1111/1467-7717.00225
Van Herp M, Parqué V, Rackley E, Ford NP
Disasters. 1 June 2003; Volume 27 (Issue 2); 141-153.; DOI:10.1111/1467-7717.00225
The people of the Democratic Republic of Congo for decades have been living in a situation of chronic crisis. Violence, population displacement and the destruction of infrastructure and health services have devastated the health of the population. In 2001, Médicins Sans Frontières conducted a survey in five areas of western and central DRC to assess mortality, access to health-care, vaccination coverage and exposure to violence. High mortality rates were found in front-line zones, mainly due to malnutrition and infectious diseases. In Basankusu approximately 10 per cent of the total population and 25 per cent of the under-five population had perished in the year before the survey. Humanitarian needs remain acute across the country, particularly near the front line. Infectious-disease control and treatment are a priority, as is increasing access to health-care. Humanitarian assistance must be increased considerably, especially in rural areas and zones that have been affected directly by conflict.
Journal Article > CommentaryFull Text
PLOS Med. 14 February 2020; Volume 17 (Issue 2); e1003028.; DOI:10.1371/journal.pmed.1003028.
Ford NP, Geng EH, Ellman T, Orrell C, Ehrenkranz PD, et al.
PLOS Med. 14 February 2020; Volume 17 (Issue 2); e1003028.; DOI:10.1371/journal.pmed.1003028.
Journal Article > ResearchFull Text
PLOS Med. 1 February 2005; Volume 2 (Issue 2); DOI:10.1371/journal.pmed.0020014
Dentico N, Ford NP
PLOS Med. 1 February 2005; Volume 2 (Issue 2); DOI:10.1371/journal.pmed.0020014
Journal Article > ReviewAbstract
J Acquir Immune Defic Syndr. 25 January 2019; Volume 80 (Issue 5); DOI:10.1097/QAI.0000000000001957
O'Brien DP, Ford NP, Djirmay AG, Calmy A, Victoria M, et al.
J Acquir Immune Defic Syndr. 25 January 2019; Volume 80 (Issue 5); DOI:10.1097/QAI.0000000000001957
Evidence suggests that there are important interactions between HIV and Female Genital Schistosomiasis (FGS) that may have significant effects on individual and population health. However, the exact way they interact and the health impacts of the interactions are not well understood. In this paper we discuss what is known about the interactions between FGS and HIV, and the potential impact of the interactions. This includes the likelihood that FGS is an important health problem for HIV positive women in schistosoma-endemic areas potentially associated with an increased risk of mortality, cancer and infertility. Additionally, it may be significantly impacting the HIV epidemic in sub-Saharan Africa by making young women more susceptible to HIV. We call for immediate action and argue that research is urgently required to address these knowledge gaps and propose a research agenda to achieve this.